Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.762213
Title: Biosimilars : market analysis and survey of factors influencing prescribing
Author: Aladul, Mohammed
ISNI:       0000 0004 7655 7972
Awarding Body: Keele University
Current Institution: Keele University
Date of Award: 2018
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Restricted access.
Access from Institution:
Abstract:
Background: Biological medicines are effective but expensive options for treating patients with chronic and life-threatening diseases unresponsive to conventional small molecule medicines. The importance of biosimilars as an alternative to expensive originator biologics in treatment regimens is increasing year by year. This thesis aimed to examine the prescribing pattern of current marketed biosimilars and understand the potential factors influencing their prescribing in UK. Methods: Examples of generic medicines entry were analysed and compared and contrasted with the entry of biosimilars in both primary and secondary care settings. Web-surveys were conducted with 234 healthcare professionals (HCPs) and 182 service users to investigate their knowledge and attitudes towards biosimilars. Face-to-face semi-structured interviews were then conducted with 26 HCPs and service users to further elucidate interviewee’s perceptions of biosimilars. Results: Findings from the market analyses showed that the penetration of a generic and/or a biosimilar is governed by the cost, the number of products (competitors) and chronicity of use when the delivery devices are the same. When delivery device or another factor influencing prescribers’ perceptions of patient benefit differed, biosimilar uptake was inhibited. The findings from web surveys and interviews showed that both HCPs and service users had a good knowledge and understanding of biosimilars and their importance for cost savings. Concerns about safety and efficacy of biosimilars during the process of switching to biosimilars were expressed by HCPs and services users, although the extent of this concern varied with the clinical discipline. Conclusion: The introduction of biosimilars is associated with considerable cost savings to the NHS. There are subtle differences between specialists’ views on biosimilars and different uptake patterns. Factors influencing prescribing biosimilar medicines were similar but more complicated than generic medicines. Cost is a key driver for the uptake of biosimilars only when patients related factors were justified or equal.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.762213  DOI: Not available
Keywords: RS Pharmacy and materia medica
Share: